Reuters logo
Drugmaker Hikma cuts generics sales forecast a third time
November 9, 2017 / 7:51 AM / a month ago

Drugmaker Hikma cuts generics sales forecast a third time

Nov 9 (Reuters) - Hikma Pharmaceuticals Plc on Thursday lowered 2017 revenue guidance for its generics business for a third time.

The Jordan-based firm, which makes and markets branded and non-branded generic and injectable drugs, said it expected revenue of around $600 million and a core operating margin in the low single-digits from its generics business.

In August it had lowered its generics revenue guidance by $50 million to about $620 million, having slashed it to $670 million from an initial $800 million last November.

Reporting by Justin George Varghese in Bengaluru; editing by Jason Neely

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below